TD Cowen raises UnitedHealth stock price target to $430 on MA trends

TD Cowen raised its UnitedHealth (UNH) price target to $430 from $337 (Hold) as the stock trades at $429.09 near its 52-week high of $434.30, with the firm lifting 2026 EPS to $18.75 from $18.25 and 2027 EPS to $20.90 from $20.40 on favorable Medicare Advantage utilization trends. While lower expected contributions from pharmacy and Insight partially offset, multiple firms remain upbeat ahead of the July 16 Q2 earnings report (Bernstein: EPS $5.22 vs $4.84 consensus; Morgan Stanley: $468 Overweight). Separately, a Trump-nominated CDC director candidate plans to resign from UNH and divest if confirmed, adding a governance/removal-of-insider-overhang item into the pre-earnings narrative.

Analysis

The setup is now more about expectation management than fundamentals discovery. UNH is trading as if a clean earnings beat is already priced, so the incremental upside from another analyst target reset is limited; the bigger market mechanism is whether management can keep the Medicare Advantage cost narrative stable enough to defend an above-market multiple. If they do, the stock can keep grinding, but the burden of proof is high because the current valuation leaves little room for even a modest guide-down.

Second-order read-through matters more for peers than for UNH itself. A confirmation that MA utilization is contained would be constructive for HUM and ELV, but it is a relative positive for UNH because it tends to have better scale, data, and pricing power when the industry is disciplined. The softer commentary on pharmacy/adjacent services is a warning flag for CVS and other diversified healthcare services names: it suggests the easiest path to growth is still core insurance economics, while the lower-margin adjacencies may not be strong enough to offset pressure elsewhere.

The real catalyst window is the Q2 print and any Stars commentary, not the target change. Over 1-3 months, a favorable guide can support another leg higher, but a neutral Stars update or any signal that 2025 pricing will not fully cover cost trend would likely compress the multiple quickly. Over 6-18 months, the thesis is that sustained cost discipline could justify continued EPS compounding; the contrarian risk is that the market is extrapolating one clean quarter into a multi-year rerate before the reimbursement cycle and quality ratings are fully de-risked.

Key Decisions for Investors

• Avoid chasing UNH here; wait for the 7/16 earnings print or a post-earnings pullback. If management confirms benign MA utilization and no Stars deterioration, use that weakness to add with a 3-6 month horizon; if the stock breaks below prior support after earnings, the de-rating risk is meaningful because expectations are crowded.
• Pair trade idea: long UNH / short CVS for the next 1-3 months. The relative value case is that UNH’s core underwriting should remain cleaner while CVS still faces weaker economics in its adjacent health-services stack; stop if CVS gains on a stronger PBM/retail margin update or if UNH misses EPS/guidance.
• For more risk-controlled expression, buy a UNH Aug/Sep call spread instead of stock into earnings. The structure benefits if the print confirms the bullish estimates, but caps premium risk if the market has already fully priced the analyst optimism.
• Watch HUM and ELV as the cleaner read-through names. If UNH confirms favorable utilization, those names can re-rate on sector de-risking; if they lag UNH post-print, it signals the market is paying for scale/quality rather than industry-wide improvement.
• Set a falsifier around the earnings call: any commentary implying higher 2025 Stars pressure, a worse-than-expected medical cost trend, or management sounding cautious on MA pricing would be a signal to fade the move rather than add to it.